Concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: Is intergroup study 0099 feasible in Japanese patients?

Koichi Isobe, Hiroyuki Kawakami, Takashi Uno, Shigeo Yasuda, Takashi Aruga, Naoyuki Ueno, Tetsuya Kawata, Hisao Ito

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Since the publication of the significant results of the Intergroup Study 0099 (IGS) in 1998, radical radiation therapy (RT) with concurrent and adjuvant chemotherapy has become the standard care for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) in the United States. An update in 2001 further strengthened the findings of the interim analysis, however, no prospective randomized trials other than this study have confirmed the feasibility of this strategy. Methods: We attempted to adopt the same combined modality treatment for three consecutive Japanese patients with locoregionally advanced NPC to evaluate its toxicity and efficacy. They were planned to receive radical RT concurrently with cisplatin every 3 weeks, and to receive adjuvant chemotherapy thereafter. Results: The hematological toxicities were mild and well tolerated in all three patients; however, they all experienced severe (grade 3 and/or 4) skin reactions, pharyngitis and dysphagia, which led to the discontinuation of the planned chemotherapy. They were able to complete RT without treatment breaks, and all three patients achieved complete response at the end of treatment. However, two experienced recurrences after 8 and 10 months, respectively, and died of their disease. Conclusions: Due to these severe acute adverse events, poor compliance and unsatisfactory outcomes, we have concluded that physicians should be careful in applying the concurrent chemoradiotherapy protocol employed by the IGS for locoregionally advanced Japanese NPC patients.

Original languageEnglish
Pages (from-to)497-500
Number of pages4
JournalJapanese Journal of Clinical Oncology
Volume33
Issue number10
DOIs
Publication statusPublished - 2003 Oct 1
Externally publishedYes

Fingerprint

Chemoradiotherapy
Radiotherapy
Adjuvant Chemotherapy
Pharyngitis
Deglutition Disorders
Cisplatin
Publications
Patient Care
Therapeutics
Physicians
Recurrence
Drug Therapy
Skin
Nasopharyngeal carcinoma

Keywords

  • Concurrent chemoradiotherapy
  • Feasibility
  • Intergroup study 0099
  • NPC

ASJC Scopus subject areas

  • Oncology

Cite this

Concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma : Is intergroup study 0099 feasible in Japanese patients? / Isobe, Koichi; Kawakami, Hiroyuki; Uno, Takashi; Yasuda, Shigeo; Aruga, Takashi; Ueno, Naoyuki; Kawata, Tetsuya; Ito, Hisao.

In: Japanese Journal of Clinical Oncology, Vol. 33, No. 10, 01.10.2003, p. 497-500.

Research output: Contribution to journalArticle

Isobe, Koichi ; Kawakami, Hiroyuki ; Uno, Takashi ; Yasuda, Shigeo ; Aruga, Takashi ; Ueno, Naoyuki ; Kawata, Tetsuya ; Ito, Hisao. / Concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma : Is intergroup study 0099 feasible in Japanese patients?. In: Japanese Journal of Clinical Oncology. 2003 ; Vol. 33, No. 10. pp. 497-500.
@article{69936910434f4c6f8d62a986b7b1de5c,
title = "Concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: Is intergroup study 0099 feasible in Japanese patients?",
abstract = "Background: Since the publication of the significant results of the Intergroup Study 0099 (IGS) in 1998, radical radiation therapy (RT) with concurrent and adjuvant chemotherapy has become the standard care for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) in the United States. An update in 2001 further strengthened the findings of the interim analysis, however, no prospective randomized trials other than this study have confirmed the feasibility of this strategy. Methods: We attempted to adopt the same combined modality treatment for three consecutive Japanese patients with locoregionally advanced NPC to evaluate its toxicity and efficacy. They were planned to receive radical RT concurrently with cisplatin every 3 weeks, and to receive adjuvant chemotherapy thereafter. Results: The hematological toxicities were mild and well tolerated in all three patients; however, they all experienced severe (grade 3 and/or 4) skin reactions, pharyngitis and dysphagia, which led to the discontinuation of the planned chemotherapy. They were able to complete RT without treatment breaks, and all three patients achieved complete response at the end of treatment. However, two experienced recurrences after 8 and 10 months, respectively, and died of their disease. Conclusions: Due to these severe acute adverse events, poor compliance and unsatisfactory outcomes, we have concluded that physicians should be careful in applying the concurrent chemoradiotherapy protocol employed by the IGS for locoregionally advanced Japanese NPC patients.",
keywords = "Concurrent chemoradiotherapy, Feasibility, Intergroup study 0099, NPC",
author = "Koichi Isobe and Hiroyuki Kawakami and Takashi Uno and Shigeo Yasuda and Takashi Aruga and Naoyuki Ueno and Tetsuya Kawata and Hisao Ito",
year = "2003",
month = "10",
day = "1",
doi = "10.1093/jjco/hyg094",
language = "English",
volume = "33",
pages = "497--500",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma

T2 - Is intergroup study 0099 feasible in Japanese patients?

AU - Isobe, Koichi

AU - Kawakami, Hiroyuki

AU - Uno, Takashi

AU - Yasuda, Shigeo

AU - Aruga, Takashi

AU - Ueno, Naoyuki

AU - Kawata, Tetsuya

AU - Ito, Hisao

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Background: Since the publication of the significant results of the Intergroup Study 0099 (IGS) in 1998, radical radiation therapy (RT) with concurrent and adjuvant chemotherapy has become the standard care for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) in the United States. An update in 2001 further strengthened the findings of the interim analysis, however, no prospective randomized trials other than this study have confirmed the feasibility of this strategy. Methods: We attempted to adopt the same combined modality treatment for three consecutive Japanese patients with locoregionally advanced NPC to evaluate its toxicity and efficacy. They were planned to receive radical RT concurrently with cisplatin every 3 weeks, and to receive adjuvant chemotherapy thereafter. Results: The hematological toxicities were mild and well tolerated in all three patients; however, they all experienced severe (grade 3 and/or 4) skin reactions, pharyngitis and dysphagia, which led to the discontinuation of the planned chemotherapy. They were able to complete RT without treatment breaks, and all three patients achieved complete response at the end of treatment. However, two experienced recurrences after 8 and 10 months, respectively, and died of their disease. Conclusions: Due to these severe acute adverse events, poor compliance and unsatisfactory outcomes, we have concluded that physicians should be careful in applying the concurrent chemoradiotherapy protocol employed by the IGS for locoregionally advanced Japanese NPC patients.

AB - Background: Since the publication of the significant results of the Intergroup Study 0099 (IGS) in 1998, radical radiation therapy (RT) with concurrent and adjuvant chemotherapy has become the standard care for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) in the United States. An update in 2001 further strengthened the findings of the interim analysis, however, no prospective randomized trials other than this study have confirmed the feasibility of this strategy. Methods: We attempted to adopt the same combined modality treatment for three consecutive Japanese patients with locoregionally advanced NPC to evaluate its toxicity and efficacy. They were planned to receive radical RT concurrently with cisplatin every 3 weeks, and to receive adjuvant chemotherapy thereafter. Results: The hematological toxicities were mild and well tolerated in all three patients; however, they all experienced severe (grade 3 and/or 4) skin reactions, pharyngitis and dysphagia, which led to the discontinuation of the planned chemotherapy. They were able to complete RT without treatment breaks, and all three patients achieved complete response at the end of treatment. However, two experienced recurrences after 8 and 10 months, respectively, and died of their disease. Conclusions: Due to these severe acute adverse events, poor compliance and unsatisfactory outcomes, we have concluded that physicians should be careful in applying the concurrent chemoradiotherapy protocol employed by the IGS for locoregionally advanced Japanese NPC patients.

KW - Concurrent chemoradiotherapy

KW - Feasibility

KW - Intergroup study 0099

KW - NPC

UR - http://www.scopus.com/inward/record.url?scp=0642372943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0642372943&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyg094

DO - 10.1093/jjco/hyg094

M3 - Article

C2 - 14623916

AN - SCOPUS:0642372943

VL - 33

SP - 497

EP - 500

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 10

ER -